Furthermore, mortality and morbidity data from over six dozen nations indicate a strong relationship between access to HCQ and COVID-19 death rates.124,125 While such a relationship does not prove cause/effect, it would be lunacy to simply ignore the reality and assume no relationship.
Country by country, data consistently links broader access to HCQ to lower mortality. The very poorest countries—if they used HCQ—had far lower case fatality rates than wealthy countries that did not. Even impoverished African nations, where “experts” like Bill Gates predicted the highest death rates, had drastically lower mortalities than in nations that banned HCQ. Senegal and Nigeria, for example, both use hydroxychloroquine and had COVID fatality rates that were significantly lower than those experienced in the United States.126
Similarly, despite the fact that hygiene in those countries is often far inferior, in Ethiopia,127 Mozambique,128 Niger,129 Congo,130 and Ivory Coast,131 there are far fewer per capita deaths than in the US. In those nations, death rates vary between 8 and 47.2 deaths per million inhabitants as of September 24, 2021. In contrast, western countries that denied access to HCQ experienced numbers of coronavirus deaths per million inhabitants between 220 per million in Holland,132 2,000 per million in the US, and 850 deaths per million in Belgium.133 Dr. Meryl Nass observed, “If people in these malaria countries would boost their immune system with zinc, vitamin C and vitamin D, the coronavirus death toll would even further decrease.”
Similarly, Bangladesh CFR, Senegal, Pakistan, Serbia, Nigeria, Turkey, and Ukraine all allow unrestricted use of HCQ and all have miniscule case fatality rates compared to the countries that ban HCQ.134 Wealthier democracies or countries with especially restrictive HCQ protocols—Ireland, Canada, Spain, the Netherlands, UK, Belgium, and France—are comparatively deadly environments.
Andrew Schlafly observed that, “The mortality rate from COVID-19 in countries that allow access to HCQ is only one-tenth the mortality rate in countries where there is interference with this medication, such as the United States. . . . In some areas of Central America, officials are even going door to door to distribute HCQ. . . . These countries have been successful in limiting the mortality from COVID-19 to only a fraction of what it is in wealthier countries.”135
As the industry/government cartel ramped up its campaign to keep HCQ from the masses, many doctors fought back. On July 23, Yale virologist Dr. Harvey Risch persisted, this time with a Newsweek article titled “The key to defeating COVID-19 already exists. We need to start using it.”136 Dr. Risch beseeched the authorities: HCQ saves lives and its use could quickly end the pandemic. By then, Dr. Risch had updated his rigorous analysis of the early treatment of COVID-19 with hydroxychloroquine, zinc, and azithromycin. He now cited twelve clinical studies suggesting that the early administration of HCQ could lower death rates by 50 percent. In that case, COVID-19 would have a lower case fatality rate than the seasonal influenza. “We would still have had a pandemic,” Harvey Risch told me, “but we wouldn’t have had the carnage.”
Noting more than fifty HCQ studies, Dr. Meryl Nass, in June 2020, supported Risch’s calculation: “If people were treated prophylactically with this drug (using only 2 tablets weekly) as is done in some areas and some occupational groups in India, there would probably be at least 50 percent fewer cases after exposure.”137 Stopping the pandemic in its tracks seemed to be the last thing Tony Fauci wanted. Thanks to Dr. Fauci, most US states had by then banned treatment with HCQ, including Dr. Nass’s home state of Maine, which banned it for prophylaxis, but did allow it for acute treatment. Dr. Nass suggested that the “acts to suppress the use of HCQ [were] carefully orchestrated” and that “these events [might] have been planned to keep the pandemic going to sell expensive drugs and vaccines to a captive population.”138
In the same article by Dr. Meryl Nass, published on June 27, 2020,139 Nass—who has extensively studied HCQ—pointed out that with prophylactic treatment with HCQ “at the onset of their illness, over 99 percent would quickly resolve the infection, avoiding progression to the late-stage disease characterized by cytokine storm, thrombophilia, and organ failure. Despite claims to the contrary, this treatment is very safe, yet outpatient treatment is banned in the United States.”
Beginning June 27, 2020, Dr. Nass began a list of deceptive strategies that the Fauci/Pharma/Gates cartel used to control the narrative on hydroxychloroquine and deny Americans access to this effective remedy. The list has grown to 58 separate strategies.140 “It is remarkable,” she observed, how “a large series of events taking place over the past months produced a unified message about hydroxychloroquine (HCQ) and produced similar policies about the drug in the US, Canada, Australia, New Zealand and western Europe. The message is that generic, inexpensive hydroxychloroquine (costing only $1.00 to produce a full course) is dangerous.”141
Dr. Fauci’s Hypocritical HCQ Games
In his early AIDS days, Dr. Fauci had thrashed FDA as inhumane for demanding randomized double-blind placebo studies at the height of the pandemic. Now, here he was doing what he had condemned by blocking an effective treatment simply because it would compete with his expensive patent-protected pharmaceutical, remdesivir, and vaccines.
*
Dr. Fauci repeatedly insisted he would not allow HCQ for COVID-19 until its efficacy is proven in “randomized, double-blind placebo studies.”142 Dr. Risch calls this position a “transparent sham.” Dr. Fauci knew that neither industry nor its PI’s would ever sponsor trials for a product with expired patents. It’s noteworthy that while Dr. Fauci was bemoaning the lack of evidence of HCQ efficacy, he was refusing to commission his own trials to study early use of the hydroxychloroquine, zinc, and Zithromax remedy. Dr. Fauci himself, while spending 48 billion dollars on zero-liability vaccines, at first refused to allocate anything for a randomized placebo study of HCQ. Even worse, he cancelled two NIAID-sponsored trials of outpatient HCQ before completion.143